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ILLUSTRATIVE CASE
A 44-year-old woman with a family history of 
early CHD is considering hysterectomy for 
painful uterine fi broids. She’s thinking about 
undergoing concurrent bilateral oophorec-
tomy to prevent ovarian cancer and asks for 
your input. How would you advise her? 
Hysterectomy is the most com-mon gynecologic surgery in the United States. In 2003, more 
than 600,000 hysterectomies were per-
formed; 89% were not associated with 
malignancies.2 
❚  Ovarian conservation 
is not the norm
Data from the University Health-
System Consortium Clinical Data-
base indicate that between 2002 and 
2008, about 55% of women who had 
a hysterectomy that was not cancer-
related underwent oophorectomy. Rates 
of concurrent oophorectomy included: 
• 68% of women ages 65 and older
•  77% of women ages 51 to 64 
•  48% of women ages 31 to 50 
•  3% of women ages 18 to 30. 
A recent analysis from the Centers 
for Disease Control and Prevention 
found that among women who under-
went hysterectomy for any reason be-
tween 1994 and 1998, 55% also had 
their ovaries removed.3
❚  Hormones and CHD: 
An unanswered question
Over the last several decades, there has 
been a great deal of interest in the relation-
ship between hormones and CHD, much 
of it stemming from the controversy about 
hormone replacement therapy (HRT). 
The fi ndings of the Women’s Health Ini-
tiative implicated combined exogenous 
hormones (estrogen and progestin) as a 
risk factor for CHD.4 Endogenous hor-
mone production, however, may protect 
against CHD; some studies have demon-
Advise patients undergoing 
hysterectomy for benign 
conditions that there are 
benefi ts to conserving their 
ovaries. The risk of coronary 
heart disease (CHD) and 
death is lower in women 
whose ovaries are conserved, 
compared with those who 
have had them removed.1 
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Parker WH, Broder MS, Chang E, et al. Ovarian 
conservation at the time of hysterectomy and 
long-term health outcomes in the Nurses’ Health 
Study. Obstet Gynecol. 2009;113:1027-1037.
Practice changer 
Ovary-sparing hysterectomy: 
Is it right for your patient? 
It may be, if her surgery is not cancer-related. 
Umang Sharma, MD, and
Sarah-Anne Schumann, MD 
Department of Family Medicine, 
The University of Chicago
P U R L s  E D I T O R 
John Hickner, MD, MSc
Department of Family Medicine,
Cleveland Clinic
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
478_JFP0909   478 8/18/09   12:12:23 PM
 VOL 58, NO 9 / SEPTEMBER 2009 479www.jfponline.com
strated a decreased risk of cardiovascular 
death with later age of menopause.5,6 
Current oophorectomy recommenda-
tions are age-speciﬁ c. The American Col-
lege of Obstetricians and Gynecologists 
(ACOG) recommends that strong consid-
eration be given to ovarian conservation 
in premenopausal women who are not 
at risk for ovarian cancer. For postmeno-
pausal women, however, ACOG recom-
mends consideration of oophorectomy 
as prophylaxis.7 These recommendations 
are based on expert opinion. Previous 
studies suggest that ovarian conserva-
tion may improve survival in specifi c age 
groups.8,9 The large, high-quality obser-
vational study reviewed here provides 
further guidance about the role of ovar-
ian conservation across all age groups. 
STUDY SUMMARY
❚  Oophorectomy increases 
risk of CHD and death 
This observational study1 was part of the 
Nurses’ Health Study. It included 29,380 
women, of which 16,345 (55.6%) un-
derwent hysterectomy with bilateral oo-
phorectomy and 13,035 (44.4%) had 
hysterectomy with ovarian conservation. 
Women with unilateral oophorectomy 
were excluded, as were those who had a 
history of CHD or stroke, and women for 
whom pertinent data, such as age, were 
missing. A follow-up survey was sent to 
participants every 2 years for 24 years, 
with an average return rate of 90%. 
Women who had undergone bilateral 
oophorectomy had an increased risk of 
CHD and all-cause mortality (TABLE). The 
authors estimated that with a postsurgical 
life span of approximately 35 years, every 
9 oophorectomies would result in 1 addi-
tional death. The authors also pointed out 
there were no age exceptions: Ovarian-
sparing surgery was linked to improved 
survival in every age group. 
Oophorectomy did have a protective 
effect against breast cancer, ovarian can-
cer (number needed to treat=220), and 
total cancer incidence, but it was associ-
ated with an increased incidence of lung 
cancer (number needed to harm=190) 
and total cancer mortality. There was no 
signifi cant difference in rates of stroke, 
pulmonary embolus, colorectal cancer, 
or hip fracture. 
WHAT’S NEW
❚  Ovarian conservation: 
Better for all ages 
The evidence is clear: Conserving the ova-
ries, rather than removing them, during 
hysterectomy is associated with a lower 
risk of CHD and both all-cause and 
cancer-related mortality. 
What about the patient’s age? A 2005 
analysis suggested that ovarian con-
servation conferred a survival benefi t 
compared to oophorectomy in women 
<65 years.8 Similarly, a 2006 cohort study 
found increased mortality in women 
<45 years who underwent concurrent oo-
phorectomy.9 But this is the fi rst study to 
demonstrate that ovarian-sparing surgery 
is associated with improved survival in 
women of every age group. 
CAVEATS
❚  Study sample and HRT 
use could affect outcome
The average age of patients in the treat-
ment (oophorectomy) arm was higher 
than that of patients in the control group; 
the women in the treatment group were 
older at the time of hysterectomy (46.8 vs 
43.3 years), as well. This should not bias 
the results, which were adjusted by age 
Oophorectomy (vs ovarian conservation) 
increases key risks1
RISK FACTOR MULTIVARIATE–ADJUSTED HR (95% CI) 
CHD (fatal and nonfatal) 1.17 (1.02-1.35)
Breast cancer 0.75 (0.68-0.84)
Lung cancer 1.26 (1.02-1.56)
Ovarian cancer 0.04 (0.01-0.09)
Total cancer 0.90 (0.84-0.96)
Total cancer mortality 1.17 (1.04-1.32)
All-cause mortality 1.12 (1.03-1.21) 
CHD, coronary heart disease; CI, confi dence interval; HR, hazard ratio.
TABLE
Do you advise 
women undergoing 
hysterectomy 
for benign 
conditions to:
❑  Undergo concurrent 
oophorectomy 
❑  Opt for ovarian 
conservation
❑  Opt for one or the 
other, depending on 
whether they are pre- 
or postmenopausal 
❑  Follow the 
recommendation of 
their gynecologist 
❑  Other
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and many other variables. 
Nonrepresentative sample. This group 
of nurses is not representative of the 
general population in several important 
aspects, including socioeconomic status, 
educational level, and race (94% Cauca-
sian). This may limit the generalizability 
of the fi ndings. 
Study design. The observational de-
sign and the fact that the patients them-
selves decided whether or not to undergo 
oophorectomy also raise the possibility 
of unmeasured confounding factors.
Cancer risk. Women with known 
BRCA mutations were not studied sepa-
rately, but the results were adjusted for 
family history of breast or ovarian can-
cer. The authors stated that a subgroup 
analysis of women with a family history 
of ovarian cancer had similar outcomes, 
although the data were not included
HRT use. As might be expected, pa-
tients in the oophorectomy arm of the 
study were more likely to use HRT. Since 
the completion of the study in 2000, 
practice recommendations have shifted 
against combined HRT use. Unopposed 
estrogen, which is not thought to in-
crease the incidence of cardiovascular 
disease, remains a treatment option for 
women who have undergone hysterec-
tomy and oophorectomy. But the overall 
effect of unopposed estrogen on survival 
is still uncertain.4 It is unclear how the 
recent decline in the use of exogenous 
hormones would affect these results. 
BARRIERS TO IMPLEMENTATION 
❚  FP-GYN communication 
can be difﬁ cult 
This study provides important informa-
tion for primary care physicians to dis-
cuss with female patients and their gyne-
cologists. However, some doctors may not 
have relationships with the gynecologists 
in their community, or have limited (or 
no) infl uence or input into which special-
ists their patients see. In addition, some 
gynecologists may hesitate to perform 
hysterectomy without oophorectomy in 
some cases for technical reasons.10 
Concern about prevention of ovarian 
cancer must be balanced with increased 
risk of mortality and CHD events. It may 
be helpful to tell patients who are about 
to undergo hysterectomy for a benign 
condition that women are nearly 30 times 
more likely to die of cardiovascular dis-
ease (CHD or stroke) than ovarian cancer 
(413,800/year vs 14,700/year).11 ■
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FAST TRACK
Tell patients 
undergoing 
hysterectomy 
for benign reasons 
that women are 
nearly 30 times 
more likely to die 
of cardiovascular 
disease than 
ovarian cancer. 
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